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Abstract
The sperm-specific glyceraldehyde-3-phosphate dehydrogenase (GAPDHS) isoform is a
promising contraceptive target because it is specific to male germ cells, essential for sperm
motility and male fertility, and well suited to pharmacological inhibition. However, GAPDHS is
difficult to isolate from native sources and recombinant expression frequently results in high
production of insoluble enzyme. We chose to use the Bac-to-Bac baculovirus-insect cell system to
express a His-tagged form of human GAPDHS (Hu his-GAPDHS) lacking the proline-rich N-
terminal sequence. This recombinant Hu his-GAPDHS was successfully produced in Spodoptera
frugiperda 9 (Sf9) cells by infection with recombinant virus as a soluble, enzymatically active
form in high yield, >35mg/L culture. Biochemical characterization of the purified enzyme by mass
spectrometry and size exclusion chromatography confirmed the presence of the tetrameric form.
Further characterization by peptide ion matching mass spectrometry and Edman sequencing
showed that unlike the mixed tetramer forms produced in bacterial expression systems, human his-
GAPDHS expressed in baculovirus-infected insect cells is homotetrameric. The ability to express
and purify active human GAPDHS as homotetramers in high amounts will greatly aid in drug
discovery efforts targeting this enzyme for discovery of novel contraceptives and three compounds
were identified as inhibitors of Hu his-GAPDHS from a pilot screen of 1120 FDA-approved
compounds.
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Glyceraldehyde-3-phosphate dehydrogenase, spermatogenic (GAPDHS; GenBank
Accession ID: NM_014364.4), the sperm-specific isoform of human GAPDH [1–3], is
under active study as a male contraceptive target [4–6]. Gene targeting studies in mice
provided compelling evidence that GAPDHS is required for sperm function and male
fertility in mice [6–7], and that males lacking this isozyme are infertile and produce sperm
with very low ATP levels and no progressive motility [6]. In contrast to the somatic form of
GAPDH, the sperm-specific GAPDHS possesses a unique proline-rich extension at the
amino terminus which varies between species (a 72 amino acid extension in human [1], of
which 42 residues comprise the proline-rich region (50% proline)[3]), and may mediate
binding to the fibrous sheath in the sperm flagellum [1,3,8].
The ability to identify potential drugs targeting human GAPDHS has been hindered by the
difficulties in producing sufficient soluble and active enzyme for study. Isolation of native
GAPDHS from sperm has proved challenging due to its tight association with the fibrous
sheath. The expression of recombinant GAPDH enzymes in E. coli has met with varied
success, with high production of insoluble material frequently observed [9]. A recent study
found that expression of rat GAPDHS, either as a full-length protein or a truncated protein
lacking the proline-rich N-terminus, resulted in protein that was predominantly insoluble [5].
We have had similar difficulties obtaining high yields of soluble protein when expressing
recombinant mouse or human GAPDHS in E. coli. Although native GAPDH enzymes
typically function as homotetramers (molecular mass ~150 kDa), the expression of rat
GAPDHS in E. coli resulted in mixed tetramers consisting of 1 subunit of rat GAPDHS and
3 subunits of E. coli GAPDH [5]. The generation of GAPDH heterotetrameric forms
combining purified GAPDH dimers from two different species has been reported [10–11].
Recombinant forms of GAPDH enzymes from a number of human parasites have also been
expressed in E. coli and shown to be tetrameric [12–16]. There are few reports on the
expression of recombinant GAPDH enzymes in host systems other than E. coli, and
expression of a GAPDH enzyme in Pichia pastoris yielded inactive enzyme [9]. The
eukaryotic baculovirus-insect cell system has been used to produce soluble oligomeric forms
of human GAPDH [17] and GAPDH from Schistosoma mansoni [9]. The S. mansoni
GAPDH expressed in Sf9 cells consisted of both monomeric and tetrameric forms, although
it was not determined whether the tetrameric form consisted of a single type or mixed
subunits.
Herein, we describe the expression and biochemical characterization of the sperm-specific
human GAPDHS protein in baculovirus-infected insect cells. In this system, the protein was
highly expressed as a biologically active and soluble form. Extensive analysis by mass
spectrometry and Edman sequencing demonstrated that the protein was a homotetrameric
species. The availability of this form of GAPDHS will greatly facilitate ongoing efforts to
identify novel inhibitors that may have potential as male contraceptives.
Materials and methods
Construction of the recombinant human GAPDHS baculovirus
Unless stated, all procedures were performed according to manufacturer’s procedures (Bac-
toBac™, Invitrogen). The full length gene for human sperm-specific gyceraldehyde-3-
phosphate dehydrogenase (GAPDHS) was synthesized (GeneArt, Inc.). A truncated
GAPDHS sequence lacking the proline-rich domain was generated by creating an EcoR1
restriction site upstream of residue 69 of the synthetic gene, and this region comprising
residues 69–408 was subcloned in-frame into the EcoRI and XhoI sites of a phosphatase
(CIP)-treated pFastBac HT baculovirus shuttle vector (Invitrogen). The resulting
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recombinant gene encodes 30 amino acids at the N-terminus, comprising a hexahistidine tag,
a spacer region and a TEV protease cleavage site plus the truncated GAPDHS gene (Fig. 1).
The resulting clonal DNA was sequenced across the two flanking restriction sites to verify
correct gene insertion.
The sequence-verified clone was transformed into DH10Bac, an E. coli strain carrying both
a baculovirus genome-containing plasmid and a plasmid encoding a transposase enzyme.
The GAPDHS gene was inserted via Tn7 transposable elements immediately downstream of
the polyhedrin promoter in the baculoviral DNA. Positive white colonies from the lacZ
DH10Bac strain were restreaked twice to ensure clonal recombinant virus. Mini-prep DNA
from the resulting white colony isolates, bacmid DNA, was PCR verified for the presence of
the GAPDHS insertion, and then used in the initial Spodoptera frugiperda (Sf9)
transfection.
Sf9 cell maintenance
Spodoptera frugiperda (Sf9) cells (ATCC) adapted to HyQ SFX-Insect serum free medium
(HyClone) supplemented with 2 mM L-glutamine and 1× Penicillin/Streptomycin were
cultured at 27°C in either monolayer or suspension culture. Sf9 suspension cultures were
maintained at a cell density of 0.5 × 106 to 3 × 106 cells/ml as 80 ml cultures in 250 ml
shaker flasks shaken at 115 rpm in an ATR Multitron shaking incubator (ATR, Inc.)
Insect cell transfection and recombinant virus isolation
To generate viral particle formation, newly attached Sf9 cells in 6-well plates (9 × 105 cells/
well) were transfected with the PCR-verified recombinant GAPDHS bacmid DNA (1–2 μg)
in Cellfectin™ (Invitrogen) and incubated in unsupplemented Sf-900 II SF medium
(Invitrogen for 5 h at 27°C. After aspiration of the transfection mixture, TNM-FH medium
(HyClone) supplemented with 10% FBS, 2 mM L-glutamine and 1x Penicillin/Streptomycin
was added. Conditioned medium was collected 5 d after transfection and the supernatant
was reserved as P1 viral stock. P2 and P3 viral amplification was accomplished in 75 cm2 T-
flasks at a multiplicity of infection (MOI) of 0.1 assuming titers of 1 × 106 and 2 × 107
plaque forming units (pfu)/ml for P1 and P2 viral stocks, respectively. The resulting P3 viral
stock was titered via the end-point dilution method [18], and determined to be 2 × 108 pfu/
ml.
Expression optimization of recombinant Hu his-GAPDHS in Sf9 cells
Optimization of protein expression was performed in 6-well plates by varying multiplicity of
infection (MOI, values of 1, 2, 5, 10 and 20) and time of expression (24, 48, 72 and 96 h).
Cells were seeded at 2 × 106 cells/well, and baculovirus stock added in 2.5 ml supplemented
(as described above) HyQ SFX-Insect medium. At regular time points, cells were washed
with PBS, harvested, and protein expression in the conditioned medium and cell pellet
assessed by SDS-PAGE.
Small scale expression and optimization of purification of Hu his-GAPDHS
Small scale expression and optimization of purification was done in 25 cm2 T-flasks; 6 ×
106 Sf9 cells were seeded per T-flask, infected at MOI 10 in supplemented HyQ SFX-Insect
medium, and harvested 72 h post infection. Cells were washed with ice-cold PBS, harvested
by centrifugation (233 × g for 10 min) and cells lysed with 25 mM Tris-HCl pH 8.0, 300mM
NaCl, 10mM imidazole, 17% glycerol, 0.1% Triton X-100, 2.5U/ml Benzonase (Novagen),
and 1 mM PMSF. After incubation on ice for 30 min at 4°C, the crude lysate was collected
by centrifugation. All purification steps were performed at 4°C. Crude lysate was incubated
with pre-equilibrated Ni2+-NTA His-Bind resin (Novagen) for 1 h to allow binding of
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recombinant GAPDHS. The resin was recovered by centrifugation at 233 × g for 1 min,
washed five times with 5 resin volumes of Ni2+-NTA binding buffer (25 mM Tris-HCl pH
8.0, 300 mM NaCl, 20 mM imidazole and 1 mM PMSF) and eluted with 3 resin volumes of
Ni2+-NTA binding buffer containing 250 mM imidazole. Following the incubation, the
sample was centrifuged and the supernatant taken as the purified protein fraction. Fractions
were analyzed by SDS-PAGE.
Large scale production and purification of recombinant Hu his-GAPDHS
For large scale production, Sf9 suspension culture (600 ml of 1.4 × 106 cells/ml) in a 2 L
shaker flask was grown in supplemented HyQ SFX-Insect medium, infected at an MOI of 5
and cultured at 27°C in a Multitron (ATR, Inc.) shaking incubator at 72 rpm. Cells were
harvested 64 h post-infection and recovered from conditioned medium by centrifugation at
2000 × g for 20 min. Crude cell extracts were prepared by resuspending the cell pellet in ice-
cold lysis buffer. After 2 h on ice, centrifugation at 1,000 × g for 10 min at 4°C was used to
pellet cell debris and separate the crude lysate. The clarified, crude lysate was incubated
with pre-equilibrated Ni2+-NTA His-Bind resin (Novagen) at a ratio of 1 ml beads/100 ml
lysate for 1 h at 4°C. After binding, the resin was recovered by centrifugation at 233 × g for
7 min, washed five times with 5 resin volumes of Ni2+-NTA binding buffer and eluted with
3 resin volumes of Ni2+-NTA binding buffer containing 175 mM imidazole. Fractions were
aliquoted and stored at −80°C.
SDS-PAGE and Western blot analysis
Proteins were analyzed by SDS-PAGE (4–12% Bis-Tris gels, NuPAGE MOPS SDS running
buffer, Invitrogen) and stained for protein with Coomassie Blue. Protein concentration was
determined by Bradford assay (Biorad). For Western blotting, protein samples were
separated by SDS-PAGE and electrophoretically transferred to PVDF at 30 V constant for 1
h using a Novex apparatus (Invitrogen). Membranes were incubated in TBS-T blocking
buffer (Tris buffered saline, 0.1% Tween-20, 5% dry milk) at room temperature for 1 h.
Blocked membranes were probed with either a GAPDHS-specific antibody (raised to
residues 159–194 of mouse GAPDHS [8]) diluted 1:3000 in blocking buffer followed by
horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (H+L) (1:5000, Pierce) or
with a penta-his HRP conjugate (1:2000, Qiagen). Membranes were washed 3 times for 3
min each in TBS-T, visualized using SuperSignal West Dura Extended Duration Substrate
chemiluminescent kit (Pierce) and detected using a Kodak Image Station 4000R.
Size exclusion chromatography
Protein size was determined by size exclusion chromatography at 15°C using an Akta FPLC
system (GE Healthcare) fitted with a Superose 12 10/300 GL column. Potassium phosphate
buffer (50 mM, pH 7.0) containing 150 mM NaCl served as the mobile phase at a flow rate
of 0.5 ml min−1. Proteins from low and high molecular weight calibration kits (GE
Healthcare) were used to estimate apparent molecular size. Kav values were calculated as in
[19].
Electroblotting and Edman sequencing
Proteins were separated by SDS-PAGE (4–12% Bis-Tris gels, NuPAGE MOPS SDS
running buffer, Invitrogen) and then transferred in 100 mM CAPS pH 11 to sequencing
grade PVDF (GE Water & Process Technologies) at 30 V constant for 1 hr. Membranes
were stained with Coomassie Blue R-250 for 3 min and bands excised for tryptic peptide
analysis. N-terminal Edman sequencing (7 cycles) was performed on separated peptides at
the University of Texas protein chemistry core using a Procise cLc 494 protein sequencer
(Applied Biosystems).
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Whole mass measurement by MALDI-TOF mass spectrometry
Purified Hu his-GAPDHS was desalted using a C4 ZipTip (Millipore Co.). The sample was
deposited onto an α-cyano-4-hydroxycinnamic acid matrix prepared in an aqueous solvent
containing 50% acetonitrile and 10 mM ammonium citrate. Protein mass was determined
using a matrix assisted laser desorption ionization (MALDI) time-of-flight (TOF) mass
spectrometer (MS) (Applied Biosystems 4800) with a mass range setting of 10,000 to
50,000 amu. Bovine serum albumin served as the calibrant. Mass spectrometry experiments
were performed at the University of North Carolina at Chapel Hill Michael Hooker
Proteomics Center.
Peptide mass fingerprinting
Peptides were generated by in-gel tryptic digestion of a Coomassie Blue stained protein
band excised from a 1D SDS-PAGE gel. Resulting peptides were analyzed using MALDI
TOF/TOF MS (Applied Biosystems 4800) as previously described [20]. Observed peptide
masses were compared to the NCBInr database using MASCOT MS/MS Ions search
algorithm (Matrix Science: www.matrixscience.com). Mass spectrometry analysis was
completed at the University of North Carolina at Chapel Hill Michael Hooker Proteomics
Center.
Enzymatic assay for GAPDHS
The dehydrogenase activity of GAPDHS was measured kinetically by monitoring the
accumulation of NADH at 340 nm [21] immediately following the addition of the substrate,
DL-glyceraldehyde-3-phosphate (GAP) (Sigma G5251). One enzyme unit is defined as the
amount of enzyme necessary for the formation of 1 μmol of 1,3-diphosphoglycerate min−1.
For Km determination for GAP, the reaction mixture contained GAPDHS, 50 mM glycine,
50 mM potassium phosphate, 5 mM EDTA, pH 8.9, 0.5 mM NAD and varying
concentrations of GAP.
Pilot high throughput screen
The high throughput screen (HTS) assay is based on the standard colorimetric assay of
GAPDH activity described above. All steps were carried out in 384-well plates at room
temperature. The assay consisted of two 25 μl additions carried out using a Multidrop liquid
dispenser (Thermo Scientific). The final assay (50 μl) contained 30 nM GAPDHS, 50 mM
glycine, 50 mM potassium phosphate, 5 mM EDTA, pH 8.9, 0.5 mM NAD and 0.5 mM
GAP. Kinetic reads (at 30 sec intervals for 5 mins) of the plates were carried out on a
Spectramax Plus 384 reader (Molecular Devices). The Prestwick collection (Prestwick
Chemical Co.) containing 1,120 FDA approved compounds was prepared as 10 mM stocks
in 100% DMSO. Compounds (0.5 μl) were pre-spotted into the 384-well plates using a
Biomek NX workstation to give a final screening concentration of 10 μM. Inhibition data
was analyzed in ActivityBase (IDBS Inc.) and using Excel.
Results
Generation of bacmid virus for recombinant human GAPDHS protein expression
We expressed a recombinant form of the human GAPDHS that lacks the proline-rich N-
terminal domain (Fig. 1) in the eukaryotic bacmid-Spodoptera frugiperda insect cell
expression system. GAPDHS lacking the proline-rich region has previously been shown to
be active [5] and the variable length of this region between species [3] suggests that its
predominant role is in localizing the enzyme to the fibrous sheath and is not critical for
function [1]. Advantages of the baculovirus-insect cell system include high expression,
correct folding, potential post-translational modifications and the production of biologically
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active protein. The recombinant GAPDHS comprised residues 69 to 408 of the full-length
enzyme (GenBank Accession ID: NP_055179.1) with an additional 30 amino acid residues
for a cleavable hexahistidine tag fused onto the N-terminus (Hu his-GAPDHS) (Fig. 1).
From the amino acid sequence for the recombinant Hu his-GAPDHS (Fig. 2; for
simplification the first residue in recombinant Hu his-GAPDHS is referred to as number 1),
a predicted mass of 40,779.41 kDa was calculated using the Swiss-Prot ExPASy Compute
pI/Mw tool.
The synthetic gene for human GAPDHS was subcloned into the baculovirus shuttle vector
pFastBac HT. The presence of insert was verified by restriction digest with EcoR1 and Xho1
which generated a band of ~1 kb that closely corresponded to the expected 1032 bp
GAPDHS gene insert (data not shown). Sequencing across the insertion sites was also used
to verify insertion. Due to the large size of the bacmid it is difficult to verify inserts by
restriction digest and so PCR amplification of the bacmid DNA gene cassette insertion with
the M13 forward and reverse primer pair was used to confirm the size of the insert, which
yielded a band of ~3.5 kb corresponding closely to the predicted 3462 bp size (data not
shown).
Expression and purification of recombinant human his-GAPDHS in Sf9 Cells
Optimization of expression in Sf9 cells was initially undertaken on a small batch scale in 6-
well plates, assessing expression in Sf9 cells at different MOI (0, 1, 2, 5, 10 and 20) and
time of harvest (48, 72, 96 h). Although expression of recombinant proteins in Sf9 cells does
not typically result in high levels of secreted recombinant protein (Bac-to-Bac, Baculovirus
Manual, Invitrogen), GAPDHS expression in both crude cell lysates (L) and conditioned
media (M) was assessed by SDS-PAGE (Fig. 3A). At all MOI tested, Sf9 cells infected with
purified recombinant human his-GAPDHS virus showed the presence of a protein with
apparent molecular weight ~40 kDa (protein band highlighted with arrow) in cell lysates that
was not present in mock transfected cells (MOI = 0) (Fig. 3A). Western blotting of the crude
lysates with an anti-Histag antibody (Fig. 3B) indicated the presence of a band at ~40 kDa in
all samples except the mock infected suggesting that this band represents the recombinant
Hu his-GAPDHS. A band corresponding to Hu his-GAPDHS was not observed in the media
fractions. After comparing expression levels using different incubation conditions, an MOI
of 10 and 72 h post-infection harvest time were chosen for subsequent protein expression
experiments.
Purification of Hu his-GAPDHS was first confirmed on a small batch scale in 25 cm2 T-
flasks (Fig. 3C). Sf9 cells were infected at an MOI of 10, and harvested 72 h post-infection.
Cells were lysed and Hu his-GAPDHS purified from the crude extract over Ni2+-NTA metal
affinity resin as described in the materials and methods. Eluted Ni2+-NTA affinity column
fractions (Fig. 3C, lane 5) from Sf9 cells infected with GAPDHS virus contained a major
band with an apparent molecular weight of ~40 kDa corresponding to Hu his-GAPDHS
which was not present in the equivalent fraction from the mock transfection (not shown). A
high degree of purification was achieved as visualized by Coomassie Blue staining of an
SDS-PAGE gel and the lack of significant lower molecular weight protein bands suggests
that proteolysis of GAPDHS was not an issue under the expression and purification
conditions used. A preliminary activity assay of the purified protein indicated good activity
(data not shown).
Large scale expression and purification of recombinant human his-GAPDHS protein in Sf9
suspension culture
To obtain sufficient purified recombinant human GAPDHS for characterization, a large-
scale suspension culture of Sf9 cells (600 ml, 1.5 × 106 cells/ml) was infected with the
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recombinant baculovirus carrying Hu his-GAPDHS. The optimal MOI of 10 and 72 h time
of harvest conditions determined in the small-scale expression studies described above were
first used in an initial 80 ml suspension culture expression experiment. However, cell
viability at time of harvest was determined to be only 60.1% (data not shown). Hence, to
minimize loss of cell viability and resulting loss of protein due to cell lysis, an MOI of 5 was
used and cell number and cell viability monitored throughout the infection process to
determine the optimal time of harvest as 64 h. These infection and culture conditions were
used for the subsequent large scale expression studies. For the 600 ml culture, cells were
collected, lysed and the Hu his-GAPDHS purified by one-step Ni2+-NTA metal affinity
chromatography using an optimized concentration of 175 mM imidazole to elute the Hu his-
GAPDHS from the resin. High purity of Hu his-GAPDHS was achieved by this Ni2+-NTA
metal affinity step as assessed by Coomassie Blue-stained (Fig. 4A, lane 1) and silver-
stained (Fig. 4A, lane 2) SDS-PAGE gels. Approximately 21 mg of Hu his-GAPDHS was
purified from a 600 ml Sf9 culture giving a yield of 35 mg/L. The yield of ~35 mg/L from
the large scale study is in line with those typically reported [22] wherein “high-level” is
defined as >100 mg of recombinant protein per liter of infected cells. The expression level
we observed in our large scale suspension culture studies was higher than in our preliminary
small scale experiments and may be attributed to a number of potential factors including
differences in cell culture conditions between the small and large scale cultures (MOI, time
of harvest and aeration). Such differences led to lower viability of the cells at small scale
and subsequent lower yield of recombinant Hu his-GAPDHS protein.
The Hu his-GAPDHS eluted from the Ni2+-NTA metal affinity column was further analyzed
by Western blotting with an anti-GAPDHS antibody [8] and an anti-Histag antibody. Since
the anti-GAPDHS antibody does not cross-react with mouse, rat or E. coli GAPDH [8], it is
unlikely that it cross-reacts with Sf9 GAPDH. On Western blots, both the anti-GAPDHS
antibody (Fig. 4A, lane 3) and the anti-Histag antibody (Fig. 4A, lane 4) reacted with a ~40
kDa band. Those results, combined with the calculated size of Hu his-GAPDHS (40 kDa,
see above) confirmed that the protein corresponding to this band was Hu his-GAPDHS.
Predicted amino acid sequence for native Spodoptera GAPDH
Extensive literature and database searching revealed no published protein sequence for Sf9
GAPDH. To identify the sequence of Sf9 GAPDH and hence its predicted molecular mass, a
search of NCBI protein databases was performed using the amino acid sequence for human
GAPDH (Accession ID: NP_002037) (corresponding to the mRNA sequence, Accession ID:
NM_002046). The most significant alignment was a 125 amino acid sequence of
Spodoptera frugiperda GAPDH corresponding to a 376 bp mRNA sequence (Accession ID:
EU372957.1). The mRNA sequence was used to BLAST the SPODOBASE Spodoptera
database of 79,148 sequences [23]. The SPODOBASE contains expressed sequence tags
(ESTs) from independent cDNA libraries including from the Sf9 cell line. The best 61
sequences (including 99% identity matches) belonged to cluster SF9L02522, which itself is
composed of 68 sequences and had been used to assemble a 1428 bp contig sequence,
SF9L02522-Contig2 (Supplemental Table 1; Supplemental Figure 1). The longest open
reading frame (ORF) from SF9L02522-Contig2 was 332 amino acids in length and had a
deduced molecular weight of 35,602 kDa for Spodoptera GAPDH. The ORF sequence was
then aligned against the human GAPDH protein sequence (335 amino acids) and revealed a
sequence identity of 76.4% (256/335) and sequence similarity of 85.7% (287/335) (data not
shown). This predicted Sf GAPDH sequence was also aligned with the Hu GAPDHS
(excluding the FastBac tag) and had 67.6% identity (230/340) (see Fig. 2, light grey
background) and 82.9% similarity (282/340) (see Fig. 2, dark grey background).
An estimation of Spodoptera GAPDH molecular weight as 37 kDa was reported previously
from SDS-PAGE analysis [24]. Protein loading SDS-PAGE gel analysis was undertaken as
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a first test for the presence of Sf9 GAPDH in the purified Hu his-GAPDHS preparation (Fig.
4B), and indicated the presence of only a single band with apparent molecular weight ~40
kDa. The 12% NuPAGE gel combined with the MOPS buffer system was chosen to give
maximal separation in the 30–50 kDa range and no band was observed in the 35–37 kDa
range that might indicate the presence of insect-derived GAPDH in the purified enzyme.
Molecular mass and size analysis of the recombinant Hu his-GAPDHS protein
Whole mass determination of purified Hu his-GAPDHS by MALDI-TOF gave an observed
mass of 40,740.2 Da (Fig. 5) close to the predicted mass of 40,779 Da from the sequence of
Hu his-GAPDHS. No other masses were observed that might correspond to Sf9 host-derived
GAPDH and if present, we would expect at a minimum, a peak of ~1/3 intensity assuming
comparable ionization efficiencies.
Size exclusion chromatography (SEC) was used to assess both the quality and molecular
mass of Hu his-GAPDHS. Baculovirus-insect cell expressed purified Hu his-GAPDHS was
applied to a Superose 12 column and eluted as a single symmetrical peak (Fig. 6A),
suggesting the protein consists of a single well folded species. Comparison with known
protein standards (Fig. 6B) yielded a molecular size of ~130 kDa, suggesting that the protein
was still an intact oligomer. The size we observed for Hu his-GAPDHS is somewhat lower
than might be expected for a tetramer (~160 kDa). Under the same conditions, human
somatic GAPDH (from human erythrocytes, Sigma, G6019) yielded a molecular mass of
~140 kDa and further analysis of Hu his-GAPDHS in a different Tris buffer system
indicated a molecular size of ~135 kDa (data not shown). Taken together with the
difficulties in accurately assessing molecular size on Superose 12 [25], our SEC data
suggests that Hu his-GAPDHS expressed in Sf9 cells is all in a tetrameric form.
Peptide sequencing of the recombinant Hu his-GAPDHS protein expressed in Sf9
Mass spectrometry and N-terminal Edman sequencing were used to assess the homogeneity
among primary amino acid sequences in the purified Hu his-GAPDHS. For MS analysis,
purified Hu his-GAPDHS was subjected to SDS-PAGE, the Coomassie Blue-stained band
was excised from the gel and peptide mass fingerprinting carried out as described in
materials and methods. Twenty two unique peptides were extracted and analyzed by peptide
mass fingerprinting and MS/MS peptide fragment ion matching (Table 1). The observed
masses of all the peptides matched (Δ<42 ppm) the calculated masses of the expected
peptides resulting from tryptic cleavage of human GAPDHS and provided 65% coverage of
the sequence (Table 3, shaded region). Other than methionine oxidation on some of the
peptides, no other modifications were observed. Observed peptide masses were compared to
the NCBInr database using MASCOT software [26] and five significant (p< 0.05) database
matches were detected, all corresponding to human sperm-specific GAPDHS. The best
database match (GenBank ID: 238537990) had a probability based MOWSE score of 803
providing high statistical confirmation that all the identified peptides come from human
GAPDHS.
For Edman sequencing, no sequence was obtained from the purified protein in solution,
suggesting a blocked N-terminus. To obtain internal sequences, purified Hu his-GAPDHS
was subjected to SDS-PAGE, transferred to a PVDF membrane and stained with Coomassie
Blue as described in materials and methods. Peptides generated by tryptic digest of the band
were separated by reversed-phase liquid chromatography and sequences determined by
Edman sequencing. Sequences were obtained for 13 peptides and for all peptides there was a
100% sequence match to human GAPDHS and no match to S. frugiperda GAPDH (Table 2;
Table 3, underlined sequences). Two peptides were sequenced by Edman that were not
detected by MS/MS analysis, providing overall Hu his-GAPDHS coverage of 68.5% (Table
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3). The absence of any peptides from insect-cell derived GAPDH indicates that the human
GAPDHS expressed in the baculovirus-infected insect cells is produced as a homotetrameric
form.
Enzymatic activity of purified Hu his-GAPDHS protein
The assay for NAD-dependent dehydrogenase activity using DL-glyceraldehyde-3-
phosphate (GAP) as substrate indicated that the purified his-GAPDHS expressed in the
baculovirus system was enzymatically active. The kinetic constants of the Hu his-GAPDHS
were determined by measuring initial rates at various GAP concentrations in the presence of
a constant saturating concentration (0.5 mM) of NAD. The Km value measured at room
temperature was 0.41 ± 0.06 mM and the specific activity (~28 U/mg) was in the range of
that reported for the activity of commercial preparations of somatic GAPDH purified from
human erythrocytes.
Pilot small molecule screen of Hu his-GAPDHS
Using the purified Hu his-GAPDHS expressed in the baculovirus-insect cell system, we
carried out a pilot high throughput screen in 384-well format against the Prestwick
collection, a purchased library containing 1,120 compounds, 90% of which are FDA-
approved drugs. The assay was first validated using procedures previously described for
enzyme assays [27]. The scatter plot for the Prestwick screen is shown in Fig. 7. Using a
threshold of 30% inhibition (3 SD above mean), this screen had a hit rate of 0.3%.
Discussion
Using the baculovirus-insect cell expression system, we found that the sperm specific
isoform of human glyceraldehyde-3-phosphate dehydrogenase (GAPDHS) lacking the
proline-rich N-terminus could be expressed as a soluble biologically active form with
substantially higher yields than we have achieved in E. coli, and with specific activities
comparable to GAPDH preparations that are commercially available. Previously, we and
others have not been able to express large amounts of soluble GAPDHS in E.coli [5,8], even
for constructs lacking the polyproline region [5] (D. Lamson, P. Danshina and K. P.
Williams, unpublished data). The use of a His-tagged construct enabled a rapid, high-purity,
one-step purification of Hu GAPDHS from the baculovirus-insect cell system as assessed by
silver staining and mass spectrometry. The Hu his-GAPDHS was tetrameric as determined
by size exclusion chromatography, consistent with previous reports that native GAPDH
enzymes are typically tetramers [28–29].
The ability of GAPDH to form mixed tetramers has long been known from GAPDH subunit
exchange studies in which heterotetrameric forms of GAPDH were generated from purified
rabbit- and yeast-derived GAPDH enzyme [11]. Rat GAPDHS expressed in E. coli yielded
heterotetramers consisting of 1 subunit of rat GAPDHS and 3 subunits of E. coli GAPDH
[5]. Hence, we were interested to see if human GAPDHS expressed in the baculovirus-insect
cell system would likewise yield a heterotetrameric form comprising Hu GAPDHS and
insect-cell derived GAPDH, or if a homotetrameric form of human GAPDHS would be
generated. To identify if the purified human GAPDHS expressed in the baculovirus-infected
insect cell system were homo- or heterotetrameric, we first needed to know the molecular
weight of GAPDH from Spodoptera frugiperda. Since a full-length sequence of Spodoptera
frugiperda GAPDH was not available, the human GAPDH amino acid sequence was used to
find an ortholog Sf9 GAPDH sequence which was then used to search the SPODOBASE
Spodoptera EST database. A Sf9 GAPDH contig match was found which contained an ORF
with 76.4% identity to human GAPDH and had a predicted mass of 35,602 Da. To our
knowledge this is the first published sequence for Spodoptera frugiperda GAPDH. The
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purified Hu his-GAPDHS exhibited a prominent band of ~40 kDa on Coomassie Blue
stained gels and contained no band around ~35 kDa that might correspond to Sf GAPDH. In
contrast, SDS-PAGE analysis of rat GAPDHS expressed in E. coli clearly showed the
presence of two bands corresponding to bacterial and recombinant enzyme [5].
To confirm the absence of insect-derived GAPDH in our purified Hu his-GAPDHS enzyme
preparation we undertook peptide mapping analysis by both peptide ion matching mass
spectrometry and Edman sequencing. All peptides analyzed corresponded to human
GAPDHS and no peptides were identified that matched those predicted for insect GAPDH.
Hence, our data indicates that the Hu his-GAPDHS expressed in baculovirus-infected insect
cells yields homotetramers in contrast to the mixed tetramers seen previously for E. coli
expression.
In the baculovirus/insect system, mechanistic and titration effects may have contributed to
the formation of GAPDHS homotetramers rather than mixed tetramers composed of Hu
GAPDHS and Sf9-derived GAPDH. The dimerization domains of Sf9 GAPDH and human
GAPDHS may differ such that mixed dimers/tetramers would not occur. The dimerization
site between Hu His-GAPDHS and E.coli GAPDH (residues 149–314) share 85% sequence
identity in this region and mixed tetramers were observed [5]. The same domains in Hu
GAPDHS and Sf9 GAPDH share 80% sequence identity, which suggests that mixed
tetramers are possible. We suggest that the primary factor influencing the homogeneity of
homotetrameric GAPDHS is the high expression level achieved in the baculovirus-insect
cell system and an intrinsic property of the system where viral takeover of the host gene
expression system favors recombinant gene expression at the expense of host gene
expression. Although GAPDH is a housekeeping gene expressed at relatively high levels,
there may be conditions under which the Sf9 GAPDH concentration is sufficiently low to
preclude mixed tetramer formation, particularly since host gene expression is typically
impaired during the time of recombinant gene expression, with expression from 24–36 h
post-infection being primarily viral-specific [18]. Previous studies that expressed
recombinant GAPDH using the baculovirus-insect cell system were not characterized for
homo- versus heterotetramer content [9,17].
To demonstrate the feasibility of using purified Hu his-GAPDHS to identify enzyme
inhibitors that may serve as preliminary leads for contraceptive agents, we screened the
Prestwick library, a collection of structurally diverse FDA-approved compounds. Three
inhibitors of Hu his-GAPDHS enzyme activity were identified and will be detailed in a
forthcoming screening publication. The availability of this active homotetrameric form of
human GAPDHS produced in the baculovirus-insect cell system in relatively large quantity
will greatly facilitate ongoing efforts to use both high throughput screening of large
compound collections and structure-based drug design approaches to identify novel
inhibitors as potential male contraceptives.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Schematic diagram of full-length human GAPDHS and the recombinant human his-
GAPDHS expressed in insect cells. The sperm isozyme possesses a proline-rich domain at
the N-terminus that is not present in the somatic GAPDH isozyme. In human GAPDHS, this
extension comprises a 19 amino acid conserved sequence, 3 amino acid intervening proline
cysteine region and a 42 amino acid proline-rich region (50% proline) from residues 27–67
[3]. Numbering in this figure refers to the sequence for human sperm-specific
gyceraldehyde-3-phosphate dehydrogenase (GAPDHS) (GenBank Accession ID:
NP_055179.1). For the form of GAPDHS expressed in insect cells herein, the N-terminal
extension containing the proline-rich region was deleted (residues 1–68) and replaced by the
30 amino acid FastBac vector sequence which included a hexahistidine purification tag and
TEV protease cleavage sequence.
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Sequence alignment between recombinant human his-GAPDHS and predicted Spodoptera
frugiperda GAPDH. For simplification, residue numbering begins at 1 for the recombinant
his-GAPDHS. The 30 residue FastBac tag is shown italicized. The sequence for Spodoptera
frugiperda (Sf) GAPDH was from SF9L02522-Contig2, a contig assembled from the
SPODOBASE EST database (see supplemental Fig. 1 and supplemental Table 1). Regions
of identity are shown with a light grey background and regions of similarity with a dark grey
background.
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Optimization of recombinant human his-GAPDHS expression in Sf9 cells. A. MOI analysis
of his-GAPDHS expression. Sf9 cells were infected with recombinant GAPDHS virus at the
indicated MOI and samples of media (M) and cell lysates (L) taken 96 h post-infection were
analyzed by SDS-PAGE. Protein bands resulting from infection with the recombinant virus
carrying the gene for GAPDHS are indicated by arrows. B. Western blot analysis of cell
lysates at the indicated MOI from experiment A above using a penta-his HRP conjugated
antibody. C. Small scale expression in 25 cm2 T-flask of Hu his-GAPDHS in Sf9 cells and
Ni-NTA affinity purification. Lane M, Novex prestained protein markers; lane 1, cell lysate
from recombinant virus infected S9 cells, lane 2, mock infected Sf9 cells, lane 3, Ni-NTA
resin unbound fraction, lane 4, Ni-NTA resin wash fraction, lane 5, Ni-NTA resin eluted
fraction showing a major band at ~40 kDa corresponding to human his-GAPDHS.
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SDS-PAGE/Western blot analysis of human his-GAPDHS purified by Ni2+-NTA affinity
chromatography. A. Coomassie-Blue stained gel, lane M, Novex prestained protein markers;
lane 1, Hu his-GAPDHS, lane 2, Silver-stained gel of Hu his-GAPDHS, lane 3, Western blot
of Hu his-GAPDHS with polyclonal antibody raised to residues 159–194 of mouse
GAPDHS [8], lane 4, Western blot of Hu his-GAPDHS with penta-his HRP conjugated
antibody. B. Coomassie-Blue stained gel; lane M, Novex prestained protein markers and
indicated amounts of purified Hu his-GAPDHS.
Lamson et al. Page 16














MALDI-TOF MS spectra of purified recombinant human GAPDHS. MALDI-TOF analysis
was performed using α-cyano-4-hydroxycinnamic acid as the matrix. The peaks at
40,740.22, 20,350.85 and 10,180.70 are single-, double-, and quadruple-charge species.
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Size exclusion chromatography of purified human his-GAPDHS. A. Chromatogram of
purified Hu his-GAPDHS loaded on a Superose 12 column at 0.5 ml/min in 50 mM
potassium phosphate pH 7.0, 150 mM NaCl buffer. B. A calibration curve was created using
the elution volumes (Ve) of the following standard proteins; ferritin (Mr 440,000), aldolase
(Mr 158,000), conalbumin (Mr 75,000), ovalbumin (Mr 44,000), carbonic anhydrase (Mr
29,000), ribonuclease A (Mr 13,700). Kav values were calculated [19] using a void volume
(Vo) of 7.4 ml and included volume of 19.9 ml (Vi). The molecular size of recombinant
human his-GAPDHS was estimated to be ~130,000 (arrow).
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Pilot high throughput screen using Hu his-GAPDHS enzyme. The Prestwick compound
collection was pre-spotted (0.5 μl) in 384-well plates and the Hu his-GAPDHS enzyme
assay carried out in a final volume of 50 μl as described in materials and methods. A.
Scatterplot showing percent inhibition for compounds screened and with hits shown as
diamonds above 30% inhibition. B. Histogram of screening data showing a normal
distribution and, C. Box plot representing quantiles and outliers.
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Table 2
Edman sequencing of tryptic peptides from recombinant human his-GAPDHS














residue numbers correspond to the recombinant human his-GAPDHS sequence (Fig. 2)
b
? question mark is used as a place holder to indicate insufficient resolution in the data to identify the amino acid residue at this location in the
sequence.
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